Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21811526 | 0.93 | EPHX2 (0.41) | EPHX2TSHRHDAC1HDAC2HDAC6 | |
| SCHEMBL3992478 | 0.91 | EPHX2 (0.43) | EPHX2TSHRHDAC1HDAC2HDAC6 | |
| SCHEMBL713362 | 0.91 | EPHX2 (0.43) | EPHX2TSHRHDAC1HDAC2HDAC6 | |
| SCHEMBL10557596 | 0.91 | EPHX2 (0.43) | EPHX2TSHRHDAC1HDAC2HDAC6 | |
| SCHEMBL9862468 | 0.91 | EPHX2 (0.43) | EPHX2TSHRHDAC1HDAC2HDAC6 | |
| SCHEMBL10606 | 0.86 | HDAC6 (0.37) | EPHX2TSHRHDAC1HDAC2HDAC6 | |
| SCHEMBL134923 | 0.85 | EPHX2 (0.46) | EPHX2TSHRHDAC1HDAC2HDAC6 | |
| SCHEMBL1639757 | 0.85 | TSHR (0.50) | EPHX2TSHRHDAC1HDAC2HDAC6 | |
| SCHEMBL26118211 | 0.85 | EPHX2 (0.37) | EPHX2TSHRHDAC1HDAC2HDAC6 | |
| SCHEMBL26115881 | 0.85 | EPHX2 (0.34) | EPHX2TSHRHDAC1HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2025078982-A1 | XYLAZINE HAPTENS, IMMUNOGENS, AND PROTEIN CONJUGATES AND METHODS OF PRODUCTION AND USE THEREOF | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| CN-118440006-A | N-containing material2-Acyl-2-amino imidazole ring compound, preparation method and application thereof | 烟台新药创制山东省实验室 | 2024-08-06 | — | — | CN | disclosed |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-11958802-B2 | Migration-resistant photopolymerization sensitizer | KAWASAKI KASEI CHEMICALS LTD. (JP) | 2024-04-16 | — | — | US | disclosed |
| CN-117510491-A | Compounds and methods for rapid accelerated targeted degradation of fibrosarcoma polypeptides | 阿尔维纳斯运营股份有限公司 | 2024-02-06 | — | — | CN | disclosed |
| CN-110741004-B | Compounds and methods for rapid accelerated targeted degradation of fibrosarcoma polypeptides | 阿尔维纳斯运营股份有限公司 | 2023-10-17 | — | — | CN | disclosed |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | YALE UNIVERSITY | 2023-01-05 | — | — | US | disclosed |
| US-20220106254-A1 | MIGRATION-RESISTANT PHOTOPOLYMERIZATION SENSITIZER | KAWASAKI KASEI CHEMICALS LTD. (JP) | 2022-04-07 | — | — | US | disclosed |
| US-11173211-B2 | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| EP-2161997-A1 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE | Boger, Dale L. (US) | 2010-03-17 | — | — | EP | disclosed |
| US-20090247503-A1 | 5-DEMETHOXYFUMAGILLOL AND DERIVATIVES THEREOF | VERSITECH LIMITED (CN) | 2009-10-01 | — | — | US | disclosed |
| WO-2009117902-A1 | 5-DEMETHOXYFUMAGILLOL AND DERIVATIVES THEREOF | VERSITECH LIMITED (CN) | 2009-10-01 | — | — | WO | disclosed |
| WO-2008150492-A1 | TRICYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20080004290-A1 | Anti-Cancer Agents | THE UNIVERSITY OF QUEENSLAND (AU) | 2008-01-03 | — | — | US | disclosed |
| EP-1694640-A4 | ANTI-CANCER AGENTS | UNIV QUEENSLAND (AU) | 2007-01-10 | — | — | EP | disclosed |
| EP-1694640-A1 | ANTI-CANCER AGENTS | THE UNIVERSITY OF QUEENSLAND (AU) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005051901-A1 | ANTI-CANCER AGENTS | THE UNIVERSITY OF QUEENSLAND (AU) | 2005-06-09 | — | — | WO | disclosed |
| US-6414179-B1 | USEFUL AGENTS IN THE TREATMENT OF INFLAMMATORY DISEASES SUCH AS ASTHMA, ARTHRITIS, INFLAMMATORY BOWEL DISEASE AND NEURODEGENERATIVE DISEASES | BRISTOL-MYERS SQUIBB COMPANY | 2002-07-02 | — | — | US | disclosed |
| US-20020065246-A1 | Alpha-and beta- substituted trifluoromethyl ketones as phospholipase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11173211-B2 | Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides | CRBN, ARAF, VHL | EPHX2 1548/4885TSHR 2304/4885HDAC1 3130/4885 |
| US-20090247503-A1 | 5-DEMETHOXYFUMAGILLOL AND DERIVATIVES THEREOF | FPGS, DHFR, G6PD | EPHX2 202/4885TSHR 3239/4885HDAC1 3276/4885 |
| US-20230000994-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, ARAF, VHL | EPHX2 1548/4885TSHR 2304/4885HDAC1 3130/4885 |
| US-11958802-B2 | Migration-resistant photopolymerization sensitizer | F12, F10, PCNA | EPHX2 1534/4885TSHR 2947/4885HDAC1 1480/4885 |
| US-20220106254-A1 | MIGRATION-RESISTANT PHOTOPOLYMERIZATION SENSITIZER | F12, F10, PCNA | EPHX2 1534/4885TSHR 2947/4885HDAC1 1480/4885 |
| US-11986531-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | EPHX2 1548/4885TSHR 2304/4885HDAC1 3130/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | EPHX2 2048/4885TSHR 1899/4885HDAC1 2489/4885 |
| US-20080004290-A1 | Anti-Cancer Agents | TP53, TOP2A, MCL1 | EPHX2 3273/4885TSHR 4374/4885HDAC1 90/4885 |
| US-20020065246-A1 | Alpha-and beta- substituted trifluoromethyl ketones as phospholipase inhibitors | PLA2G4B, PLA2G1B, PLA2R1 | EPHX2 109/4885TSHR 2683/4885HDAC1 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.